87 related articles for article (PubMed ID: 7763013)
1. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.
Masumoto N; Nakano S; Esaki T; Tatsumoto T; Fujishima H; Baba E; Nakamura M; Niho Y
Anticancer Res; 1995; 15(2):405-9. PubMed ID: 7763013
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
Masumoto N; Nakano S; Esaki T; Fujishima H; Tatsumoto T; Niho Y
Int J Cancer; 1995 Jul; 62(1):70-5. PubMed ID: 7601570
[TBL] [Abstract][Full Text] [Related]
3. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Kawasaki M; Tsuruta N; Mizuno K; Hara N
Anticancer Drugs; 1997 Mar; 8(3):231-7. PubMed ID: 9095327
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
8. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
[TBL] [Abstract][Full Text] [Related]
10. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Tanaka T; Bai T; Yukawa K; Umesaki N
Oncol Rep; 2006 Apr; 15(4):939-47. PubMed ID: 16525683
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of CPT-11 and SN-38 for gastrointestinal and recurrent carcinomas cultured on contact-sensitive plates.
Matsuoka H; Furusawa M; Tomoda H; Seo Y; Kono A; Takeda S; Sato K
Anticancer Res; 1994; 14(2A):405-9. PubMed ID: 8017840
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
Yan D; Zheng X; Tu L; Jia J; Li Q; Cheng L; Wang X
Mol Med Rep; 2015 Jan; 11(1):295-302. PubMed ID: 25352209
[TBL] [Abstract][Full Text] [Related]
14. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates.
Matsuoka H; Yano K; Seo Y; Saito T; Tomoda H; Takiguchi S; Kono A
Anticancer Drugs; 1995 Jun; 6(3):413-8. PubMed ID: 7670139
[TBL] [Abstract][Full Text] [Related]
16. [Effects of SN-38 in combination with other anticancer agents against Dauji cells].
Akutsu M; Suzuki K; Tsunoda S; Kano Y; Miura Y
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1607-11. PubMed ID: 8060135
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
18. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
19. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
20. [In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines].
Nagasawa M; Ishii S; Kariya Y; Itoh O; Yamamoto H; Kawaharajo K; Takeuchi T
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):633-8. PubMed ID: 2108612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
